Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2021 16:30 ET | Source: KemPharm

KemPharm to Report First Quarter 2021 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 13, 2021, 4:30 p.m. ET CELEBRATION, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:...
April 21, 2021 16:45 ET | Source: KemPharm

KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital

Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX CELEBRATION, Fla., April 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a...
April 08, 2021 16:05 ET | Source: KemPharm

KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales Conference Call and Live Audio...
March 11, 2021 16:25 ET | Source: KemPharm

KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results

Corporate and Regulatory Highlights: AZSTARYS™ NDA approved by the FDA on March 2, 2021Co-hosted “KP415 Market Opportunity and Commercialization Strategy” Investor Event with Corium, Inc.Received FDA...
March 09, 2021 07:30 ET | Source: KemPharm

KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET CELEBRATION, Fla., March 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:...
March 04, 2021 16:41 ET | Source: KemPharm

KemPharm to Present at the 33rd Annual Roth Conference

CELEBRATION, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
March 02, 2021 23:31 ET | Source: KemPharm

KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD

Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET CELEBRATION, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty...
January 27, 2021 08:30 ET | Source: KemPharm

KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder

Financial Restructuring and Nasdaq Re-Listing Process Completed CELEBRATION, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the...
January 14, 2021 07:30 ET | Source: KemPharm

KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference

Combination of Oral and Poster Presentations Scheduled for January 15, 2021 CELEBRATION, Fla., Jan. 14, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company...
January 13, 2021 07:30 ET | Source: KemPharm

KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”

CELEBRATION, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...